History

2017: Synmosa to consolidate hold on Health Chemical in 128 million deal.; Synmosa acquired all Synpac-Kingdom Pharmaceutical’s products for 135 million.; Synmosa aquired Hitpharm Pharmaceutical.

2016: The Synmosa Group, along with InnoPharmax, merged with Seven Star Pharmaceutical Co.; Synmosa joined hands with Hemony in China for the authorized production of the nasal spray Besonin.

2015: Collaborated with KYORIN to introduce a new patent medicine for the overactive bladder.; The Synmosa hormone plant acquired Korean drug certification.

2014: Merged with Health Chemical Pharmaceutical Co Ltd; Subsidiary company Intech Biopharm was listed on the market. The new office laboratory complex in Neihu was completed and officially opened at the same time. In the same year, our MDI product was granted patents in China, Hong Kong, the United States, New Zealand, and South Korea.; U-Liang Pharmaceutical Co. obtained PIC/S GMP evaluation and an outstanding drug manufacturing certificate from the Ministry of Health and Welfare.; The Synmosa plant and U-Liang Pharmaceutical Co. obtained an outstanding vendor for Good Distribution practices GDP.

2013: Obtained the first domestic HFA MDI drug certification.; Purchased and merged with U-Liang Pharmaceutical Co.; Received MDI spray counter patent in the United States and China.; A patent for MDI manufacturing methods for treating respiratory diseases was granted in Taiwan.; Passed the Taiwan Intellectual Property Management System (TIPS) verification.; Purchased and merged with Ningbo Yohe Pharmaceutical.

2011: The sex hormone plant received PIC/S GMP evaluation.; The subsidiary Intech Biopharm was established, and became the only company in Taiwan, and of the few in the world, to develop HFA MDI medicines.; Purchased and merged with GeLi Ltd.

2009: Purchased the Boehringer Ingelheim’s asthma medication Duasma’s drug license in Taiwan.; The Synmosa plant obtained PIC/S GMP certification.

2008: Synmosa established the first HFA MDI manufacturing platform in Taiwan with special project support from the Ministry of Economic Affairs.; Merged with InnoPharmax, and continued to develop an Oralpas patent technology related product.; Constructed a designated sex hormone plant that conformed to international specifications.

2007: Worked with Sanofi-Avantis and Boehringer Ingelheim as an authorized agent and distributor.; Received exclusive authorization as the agent for Australia’s (SIR-Spheres®) selective in vivo therapy, a new treatment for terminal liver cancer patients.; Granted a preparation method patent for slow-release round-particle composite in China.; Synmosa established the HK office and acquired Hart Pharmaceutical to expand the sales network. It transformed into Synmosa Biopharm (Hong Kong) in 2009.

2006: Received exclusive technology transfer from Japan’s Kissei for Silodosin, a new patent drug for the prostate, to be distributed in Taiwan and Hong Kong.; Received patents for sustained release pellets and the preparation method in Taiwan.; Signed a letter of intent to cooperate with the Development Center for Biotechnology for lung inhalants.

2005: Purchased Boehringer Ingelheim’s Taiwan subsidiary factory (Hsinchu) and received OEM contracts for Taiwan and South Africa region drugs.; Received Kyowa-Kirin’s exclusive authorization for technology transfer of Benidipine, a new blood pressure reduction drug, to be made and sold in Taiwan.; Singapore government officials came to the Synmosa plant in Taiwan for a GMP audit.; Signed a Chinese medicine cooperative development agreement with the National Yang-Ming University Research Center for Drug Discovery.

2000 ~ 2004: Pioneered the China and Hong Kong markets.; Changed the company name to Synmosa Biopharma Corp.; Established the only domestic professional low humidity food factory.; Became a GTSM (OTC) listed company.; Completed and began operating the only professional low humidity food factory in Taiwan.

1998 ~ 1999: Completed the controlled release dosage form and microcapsule core technologies.

1992 ~ 1996: Purchased Xin-Yuan Pharmaceutical and established the cGMP production and manu- facturing development platform.

1980: Established as Formosa Time Pharmaceutical Co. and began a long-term agency relationship with Orion Pharma.; Continued as an agent for American and European drugs (including Denmark, Switzerland, Germany and the Netherlands).

Honesty • Credibility • Reliability • Innovation